Objectives-To define pulmonary involvement on high resolution computed tomography (HRCT) of the thorax in lifelong non-smoking rheumatoid arthritis patients and to relate the results to pulmonary function, bronchial reactivity, and a variety of clinical and serological factors. Methods-Twenty lifelong non-smoking RA patients (mean age 59 years (range 44-72; 18 females) were studied. Detailed medical and drug histories were taken. Protease inhibitor phenotype (Pi) and HLA-DR4 status were assessed. Schirmer's tear tests were performed to detect keratoconjunctivitis sicca (KCS). Spirometry, flow volume loops, and gas transfer factor measurement were recorded. The degree of bronchial reactivity (PC20 FEVy) was measured by a methacholine inhalation test. Chest and hand radiographs and HRCT of the lung were performed in all patients.
Objectives-To define pulmonary involvement on high resolution computed tomography (HRCT) of the thorax in lifelong non-smoking rheumatoid arthritis patients and to relate the results to pulmonary function, bronchial reactivity, and a variety of clinical and serological factors. Methods-Twenty lifelong non-smoking RA patients (mean age 59 years (range 44-72; 18 females) were studied. Detailed medical and drug histories were taken. Protease inhibitor phenotype (Pi) and HLA-DR4 status were assessed. Schirmer's tear tests were performed to detect keratoconjunctivitis sicca (KCS). Spirometry, flow volume loops, and gas transfer factor measurement were recorded. The degree of bronchial reactivity (PC20 FEVy) was measured by a methacholine inhalation test. Chest and hand radiographs and HRCT of the lung were performed in all patients. Results-Thirteen patients were HLA-DR4 positive. Eighteen had the Pi MM and two the Pi MS phenotype. Eight patients had evidence of KCS on Schirmer's tear testing. Ten Rheumatoid arthritis (RA) is associated with a variety of pulmonary complications such as pleural effusion, pulmonary nodules, pulmonary fibrosis, and bronchiectasis.1 Previous workers reporting an association of bronchiectasis and RA diagnosed the bronchiectasis on the basis of a chronic productive cough, persistent coarse crackles on chest auscultation, and an abnormal chest radiograph. It is generally accepted that the chest radiograph may be normal in patients with bronchiectasis. In the past, an invasive procedure such as bronchography was required to establish a firm diagnosis of bronchiectasis. However, high resolution computed tomography (HRCT) is a non-invasive procedure which is nowadays regarded as the most useful investigation for diagnosing the condition. 2 We have performed HRCT in 20 lifelong non-smoking asymptomatic RA patients to define pulmonary involvement and to relate the results to pulmonary function, bronchial reactivity, and a variety of clinical and serological factors.
Patients and methods
We have previously shown a significantly high prevalence of airflow obstruction and bronchial reactivity to inhaled methacholine in 100 patients with RA, compared with 50 controls.3
Of these 100 patients, 36 were lifelong nonsmokers. From this population, 20 lifelong non-smoking RA patients, all with no respiratory symptoms at the time of the study and normal chest radiographs, were recruited to the present study.
Detailed HRCT demonstrated basal bronchiectasis in five patients (25%) (duration of RA five, eight, 18, 20, and 27 years) while in one patient the lungs had the basal ground glass appearance consistent with mild interstitial lung disease. In the bronchiectasis group, two patients had a history of pleurisy, one had pneumonia, and none had a history of wheeze; none was atopic on skin prick testing. There was no evidence of adjacent scarring on HRCT in patients who had had pleurisy or pneumonia. In the bronchiectasis group, one patient was taking salazopyrin, one penicillamine, and one gold. There was no significant difference between patients with and without bronchiectasis in age, gender, and duration of RA ( 
Discussion
Although this was an uncontrolled study using a highly sensitive technique (HRCT) to detect pulmonary abnormalities, we were surprised to find that 25% of our patients had bronchiectasis. A previous study also reported a 25% incidence of bronchiectasis in their RA patients on HRCT,5 but most of those patients were smokers and had respiratory symptoms. Another study examined 18 consecutive RA patients with HRCT and reported a variety of pulmonary abnormalities such as interstitial fibrosis (eight patients) and bronchiectasis (two patients).6 Although the majority of these patients were lifelong non-smokers, 50% of them had abnormal chest radiographs. The fact that we studied only patients with a normal chest radiograph could explain the decreased frequency of interstitial lung disease observed in our patients.
It is generally believed that bronchiectasis precedes RA by many years, and that chronic suppuration in the lung leads to antigenic stimulation in susceptible individuals, causing RA; whether bronchiectasis preceded the onset of RA in our patients is difficult to establish, but none of them had any regular respiratory symptoms before the onset of RA. Another possibility is that RA or its treatment leads to an increased frequency of respiratory tract infections causing bronchiectasis. We did not observe any significant difference in the respiratory symptoms or treatment with disease modifying drugs in our patients with and without bronchiectasis. Although there was no significant difference between the duration of their RA in patients with and without bronchiectasis, in general, patients with bronchiectasis had had RA for a longer period of time than those without.
Protease inhibitor (Pi) is the predominant serum antiprotease and protects vulnerable tissue from proteolytic enzymes released by inflammatory cells. Its absence or deficiency can lead to increased tissue destruction. It is not known if the effect of mild protease inhibitor deficiency is further potentiated in RA because of pre-existing inflammation in the joints and lungs. One previous study has reported rapidly progressive airflow obstruction in three patients with Pi MS phenotypes,7
all of whom were current smokers. However, in common with two other studies,8 9 we have not found any association between bronchiectasis and Pi phenotypes in our patients.
HLA-DR4 is reported to be associated with pulmonary abnormalities in RA,"1 1 but none of these studies assessed their patients for evidence of bronchiectasis. One previous study has assessed a large number of RA patients with and without extra-articular features and reported an association of HLA with bronchiectasis in patients with RA.12 Although we did not find any significant association of HLA-DR4 and bronchiectasis in our patients, this could reflect the relatively small number of patients showing bronchiectasis in our study.
Patients with primary and secondary Sjogren's syndrome are more prone to the development of respiratory symptoms, airflow obstruction and bronchial hyperreactivity.3 13 14 Four out of five of our patients with bronchiectasis had KCS. One previous study9 also revealed an increased frequency of bronchiectasis in patients with secondary Sj6gren's syndrome. Surprisingly, patients with primary Sjogren's syndrome have not been found to have an increased frequency of bronchiectasis. One may speculate that the interaction between RA, treatment with immunosuppressive drugs, and Sjogren's syndrome, increases predisposition to the development of bronchiectasis.
In summary, using a highly sensitive technique such as HRCT, we found evidence in lifelong non-smoking RA patients to suggest that the incidence of bronchiectasis may be much higher than previously reported. 
